A late-stage drug development company specialized in oncology and endocrine therapy.

Aeterna Zentaris receives positive Scientific Tips from EMA for perifosine Stage 3 trial in colorectal cancer Aeterna Zentaris Inc. , a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it provides received positive Scientific Assistance from the European Medicines Company regarding the Phase 3 trial initiated last April for the development of its business lead anticancer proprietary substance, perifosine, in refractory advanced colorectal cancers cialisprix.net . The trial has been sponsored by Keryx Biopharmaceuticals, Inc., , , Aeterna Zentaris’ licensee for perifosine in North America.